Diametric Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-15,708
Closed -$2.13M 170
2021
Q2
$2.13M Buy
+15,708
New +$2.07M 1.54% 18
2021
Q1
Sell
-5,900
Closed -$831K 216
2020
Q4
$831K Buy
5,900
+669
+13% +$85.7K 0.66% 50
2020
Q3
$583K Buy
+5,231
New +$586K 0.43% 62

Other funds holding XBI

Diametric Capital's XBI Position: Q3 2021 in Review

Diametric Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 15,708 shares — an estimated $2.13M sold.

Diametric Capital first reported a position in XBI in Q3 2020 and held it in 3 quarters. The position peaked at $2.13M in Q2 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Diametric Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Diametric Capital sold 15,708 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $2.13M.
  • Diametric Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 3 quarters.
  • Diametric Capital's State Street SPDR S&P Biotech ETF position peaked at $2.13M in Q2 2021.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Diametric Capital's 13F filing for Q3 2021, filed 15 Nov 2021.